Neurocrine Biosciences investigates potential treatments for people living with neurological, psychiatric, endocrine and immunological disorders that lack viable options. Founded in 1992 by scientists from the Salk Institute and Stanford University, the company has developed FDA approved medicines for tardive dyskinesia, Huntington's disease, congenital adrenal hyperplasia, endometriosis and uterine fibroids. With over 2,000 employees and a robust pipeline in mid to late phase clinical development, Neurocrine continues to pursue new treatments for rare and underserved diseases. The company's work is driven by patient needs, identifying the greatest gaps and working relentlessly to bring hope to those who need it most.
2000
Team Members
1992
Founded
Pharma
Sector
Hybrid
Work Environment
A world where people living with rare and underserved neurological, endocrine and psychiatric conditions have access to treatments that relieve their suffering and restore hope.
At Neurocrine Biosciences, our mission is to relieve suffering for people with great needs by investigating and developing life changing treatments for rare and under-addressed neurological, neuroendocrine and neuropsychiatric disorders.